http://hl7.org/fhir/uv/ebm/PublicationRecord/179624
type: PublicationRecord
resource definition: 1.0
resource definition: .0
node role: treeRoot
id:
  v: 179624
meta:
  version id:
    v: 20
  last updated:
    v: 2025-10-13T12:34:35.118Z
  profile:
    v: http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation
    l: journal-article-citation
language:
  v: en
text:
  status:
    v: extensions
  div:
    v: Generated Narrative: PublicationRecord 179624 version: 20; Last updated: 2025-10-13 12:34:35+0000 Profile: JournalArticleCitation ArtifactPublicationStatus: Active url: https://fevir.net/resources/PublicationRecord/179624 identifier: FEvIR Object Identifier/179624, https://pubmed.ncbi.nlm.nih.gov/24598155 title: 24598155 Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer. status: Active author: Computable Publishing®: MEDLINE-to-FEvIR Converter: publisher: Computable Publishing LLC contact: support@computablepublishing.com description: This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide. UseContexts - Code Value[x] * Citation Classification Type: fevir-platform-use (FEvIR Platform Use) Medline Base copyright: https://creativecommons.org/licenses/by-nc-sa/4.0/ approvalDate: 2015-01-02 lastReviewDate: 2021-10-21 classification type: Citation Source classifier: MEDLINE classification type: MEDLINE Citation Owner classifier: National Library of Medicine, Index Section currentState: Medline Citation Status of Medline, PubMed PublicationStatus of epublish statusDate activity: PubMed Pubstatus of Received period: ?? --> 2013-12-27 statusDate activity: PubMed Pubstatus of Accepted period: ?? --> 2014-02-25 statusDate activity: PubMed Pubstatus of Entrez period: ?? --> 2014-03-07 06:00:00+0000 statusDate activity: PubMed Pubstatus of Pubmed period: ?? --> 2014-03-07 06:00:00+0000 statusDate activity: PubMed Pubstatus of Medline period: ?? --> 2015-01-03 06:00:00+0000 statusDate activity: PubMed Pubstatus of PMC release period: ?? --> 2014-03-05 citedArtifact identifier: https://pubmed.ncbi.nlm.nih.gov/24598155, https://www.ncbi.nlm.nih.gov/pmc//PMC3974001, https://doi.org/10.1186/1756-8722-7-20, pii/1756-8722-7-20 Titles - Type Language Text * Primary title English Long-term results of a phase II study with neoadjuvant docetaxel ch…
contained: Practitioner
  id:
    v: contributor0
  name:
    family:
      v: Thalgott
    given:
      v: Mark
contained: Practitioner
  id:
    v: contributor1
  name:
    family:
      v: Horn
    given:
      v: Thomas
contained: Practitioner
  id:
    v: contributor2
  name:
    family:
      v: Heck
    given:
      v: Matthias M
contained: Practitioner
  id:
    v: contributor3
  name:
    family:
      v: Maurer
    given:
      v: Tobias
contained: Practitioner
  id:
    v: contributor4
  name:
    family:
      v: Eiber
    given:
      v: Matthias
contained: Practitioner
  id:
    v: contributor5
  name:
    family:
      v: Retz
    given:
      v: Margitta
contained: Practitioner
  id:
    v: contributor6
  name:
    family:
      v: Autenrieth
    given:
      v: Michael
contained: Practitioner
  id:
    v: contributor7
  name:
    family:
      v: Herkommer
    given:
      v: Kathleen
contained: Practitioner
  id:
    v: contributor8
  name:
    family:
      v: Krause
    given:
      v: Bernd J
contained: Practitioner
  id:
    v: contributor9
  name:
    family:
      v: Gschwend
    given:
      v: Jürgen E
contained: Practitioner
  id:
    v: contributor10
  name:
    family:
      v: Treiber
    given:
      v: Uwe
contained: Practitioner
  id:
    v: contributor11
  name:
    family:
      v: Kübler
    given:
      v: Hubert R
contained: ArtifactAssessment
  id:
    v: meshHeading0
  artifact: Reference
    l: #
    reference:
      v: #
    type:
      v: PublicationRecord
      l: PublicationRecord
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier: D000368
    free to share:
      v: true
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier: D000726
    free to share:
      v: true
    component:
      classifier: Q000627
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier: D018450
    free to share:
      v: true
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier: http://id.nlm.nih.gov/mesh/D000077143
    free to share:
      v: true
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier: D006801
    free to share:
      v: true
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier: D008297
    free to share:
      v: true
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier: D008875
    free to share:
      v: true
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier: D020360
    free to share:
      v: true
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier: D011471
    free to share:
      v: true
    component:
      classifier: Q000188
    component:
      classifier: Q000601
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier: D016019
    free to share:
      v: true

v: mesh-heading

v: MeSH heading

v: D000368

v: Aged

v: false

v: qualifier

v: is not a major topic

v: mesh-heading

v: MeSH heading

v: D000726

v: Androgen Antagonists

v: false

v: qualifier

v: is not a major topic

v: qualifier

system:
  v: https://www.nlm.nih.gov/mesh
  l: mesh
code:
  v: Q000627
display:
  v: therapeutic use

text:
  v: is Major topic

coding:
  system:
    v: http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl
    l: Thesaurus.owl
  code:
    v: C49488
  display:
    v: Yes

v: mesh-heading

v: MeSH heading

v: D018450

v: Disease Progression

v: false

v: qualifier

v: is not a major topic

v: mesh-heading

v: MeSH heading

v: D000077143

v: Docetaxel

v: false

v: qualifier

v: is not a major topic

v: mesh-heading

v: MeSH heading

v: D006801

v: Humans

v: false

v: qualifier

v: is not a major topic

v: mesh-heading

v: MeSH heading

v: D008297

v: Male

v: false

v: qualifier

v: is not a major topic

v: mesh-heading

v: MeSH heading

v: D008875

v: Middle Aged

v: false

v: qualifier

v: is not a major topic

v: mesh-heading

v: MeSH heading

v: D020360

v: Neoadjuvant Therapy

v: false

v: qualifier

v: is not a major topic

v: mesh-heading

v: MeSH heading

v: D011471

v: Prostatic Neoplasms

v: false

v: qualifier

v: is not a major topic

v: qualifier

system:
  v: https://www.nlm.nih.gov/mesh
  l: mesh
code:
  v: Q000188
display:
  v: drug therapy

text:
  v: is Major topic

coding:
  system:
    v: http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl
    l: Thesaurus.owl
  code:
    v: C49488
  display:
    v: Yes

v: qualifier

system:
  v: https://www.nlm.nih.gov/mesh
  l: mesh
code:
  v: Q000601
display:
  v: surgery

text:
  v: is Major topic

coding:
  system:
    v: http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl
    l: Thesaurus.owl
  code:
    v: C49487
  display:
    v: No

v: mesh-heading

v: MeSH heading

v: D016019

v: Survival Analysis

v: false

type:
  text:
    v: qualifier
classifier:
  text:
    v: is not a major topic

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: mesh-heading
    display:
      v: MeSH heading
  text:
    v: components (if present) include qualifier codings
classifier: D043823
  coding:
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D043823
    display:
      v: Taxoids
    user selected:
      v: false
free to share:
  v: true
component:
  type:
    text:
      v: qualifier
  classifier:
    text:
      v: is not a major topic
component:
  type:
    text:
      v: qualifier
  classifier: Q000009
    coding:
      system:
        v: https://www.nlm.nih.gov/mesh
        l: mesh
      code:
        v: Q000009
      display:
        v: adverse effects
  component:
    type:
      text:
        v: is Major topic
component:
  type:
    text:
      v: qualifier
  classifier: Q000627
    coding:
      system:
        v: https://www.nlm.nih.gov/mesh
        l: mesh
      code:
        v: Q000627
      display:
        v: therapeutic use
  component:
    type:
      text:
        v: is Major topic

v: C49487

v: No

v: C49488

v: Yes

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: mesh-heading
    display:
      v: MeSH heading
  text:
    v: components (if present) include qualifier codings
classifier: D016896
  coding:
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D016896
    display:
      v: Treatment Outcome
    user selected:
      v: false
free to share:
  v: true
component:
  type:
    text:
      v: qualifier
  classifier:
    text:
      v: is not a major topic

url:
  v: http://hl7.org/fhir/uv/ebm/StructureDefinition/artifact-publication-status
  l: artifact-publication-status
value: CodeableConcept
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-status-type
      l: cited-artifact-status-type
    code:
      v: active
    display:
      v: Active

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/v2-0203
      l: v2-0203
    code:
      v: ACSN
    display:
      v: Accession ID
  text:
    v: FEvIR Object Identifier
system:
  v: https://fevir.net/FOI
  l: FOI
value:
  v: 179624
assigner:
  display:
    v: Computable Publishing LLC

system:
  v: https://pubmed.ncbi.nlm.nih.gov
  l: pubmed.ncbi.nlm.nih.gov
value:
  v: 24598155

v: 24598155 Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer.

v: active

name:
  v: Computable Publishing®: MEDLINE-to-FEvIR Converter

v: Computable Publishing LLC

telecom:
  system:
    v: email

v: This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.

code:
  system:
    v: http://terminology.hl7.org/CodeSystem/citation-classification-type
    l: citation-classification-type
  code:
    v: fevir-platform-use
  display:
    v: FEvIR Platform Use
value: CodeableConcept
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: medline-base
    display:
      v: Medline Base
    user selected:
      v: false

v: 2015-01-02

v: 2021-10-21

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-classification-type
      l: citation-classification-type
    code:
      v: citation-source
    display:
      v: Citation Source
classifier:
  text:
    v: MEDLINE

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-classification-type
      l: citation-classification-type
    code:
      v: medline-owner
    display:
      v: MEDLINE Citation Owner
classifier:
  coding:
    system:
      v: https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#owner_value
      l: owner value
    code:
      v: NLM
    display:
      v: National Library of Medicine, Index Section
    user selected:
      v: false

coding:
  system:
    v: http://hl7.org/fhir/uv/ebm-incubator/CodeSystem/publicationrecord-status-type
    l: publicationrecord-status-type
  code:
    v: medline-medline
  display:
    v: Medline Citation Status of Medline

coding:
  system:
    v: http://hl7.org/fhir/uv/ebm-incubator/CodeSystem/publicationrecord-status-type
    l: publicationrecord-status-type
  code:
    v: pubmed-publication-status-epublish
  display:
    v: PubMed PublicationStatus of epublish

activity:
  coding:
    system:
      v: http://hl7.org/fhir/uv/ebm-incubator/CodeSystem/publicationrecord-status-type
      l: publicationrecord-status-type
    code:
      v: pubmed-pubstatus-received
    display:
      v: PubMed Pubstatus of Received
period:
  end:
    v: 2013-12-27

activity:
  coding:
    system:
      v: http://hl7.org/fhir/uv/ebm-incubator/CodeSystem/publicationrecord-status-type
      l: publicationrecord-status-type
    code:
      v: pubmed-pubstatus-accepted
    display:
      v: PubMed Pubstatus of Accepted
period:
  end:
    v: 2014-02-25

activity:
  coding:
    system:
      v: http://hl7.org/fhir/uv/ebm-incubator/CodeSystem/publicationrecord-status-type
      l: publicationrecord-status-type
    code:
      v: pubmed-pubstatus-entrez
    display:
      v: PubMed Pubstatus of Entrez
period:
  end:
    v: 2014-03-07T06:00:00.000Z

activity:
  coding:
    system:
      v: http://hl7.org/fhir/uv/ebm-incubator/CodeSystem/publicationrecord-status-type
      l: publicationrecord-status-type
    code:
      v: pubmed-pubstatus-pubmed
    display:
      v: PubMed Pubstatus of Pubmed
period:
  end:
    v: 2014-03-07T06:00:00.000Z

activity:
  coding:
    system:
      v: http://hl7.org/fhir/uv/ebm-incubator/CodeSystem/publicationrecord-status-type
      l: publicationrecord-status-type
    code:
      v: pubmed-pubstatus-medline
    display:
      v: PubMed Pubstatus of Medline
period:
  end:
    v: 2015-01-03T06:00:00.000Z

activity:
  coding:
    system:
      v: http://hl7.org/fhir/uv/ebm-incubator/CodeSystem/publicationrecord-status-type
      l: publicationrecord-status-type
    code:
      v: pubmed-pubstatus-pmc-release
    display:
      v: PubMed Pubstatus of PMC release
period:
  end:
    v: 2014-03-05

identifier:
  system:
    v: https://pubmed.ncbi.nlm.nih.gov
    l: pubmed.ncbi.nlm.nih.gov
  value:
    v: 24598155
identifier:
  system:
    v: https://www.ncbi.nlm.nih.gov/pmc/
    l: pmc
  value:
    v: PMC3974001
identifier:
  system:
    v: https://doi.org
    l: doi.org
  value:
    v: 10.1186/1756-8722-7-20
identifier:
  type:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/v2-0203
        l: v2-0203
      code:
        v: ACSN
      display:
        v: Accession ID
    text:
      v: pii
  value:
    v: 1756-8722-7-20
title:
  type:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/title-type
        l: title-type
      code:
        v: primary
      display:
        v: Primary title
  language:
    v: en
  text:
    v: Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer.
abstract:
  type:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/cited-artifact-abstract-type
        l: cited-artifact-abstract-type
      code:
        v: primary-human-use
      display:
        v: Primary human use
  text:
    v: **BACKGROUND:** Patients with locally advanced and high-risk prostate cancer (LAPC) are prone to experience biochemical recurrence despite radical prostatectomy (RP). We evaluated feasibility, safety and activity of a neoadjuvant chemohormonal therapy (NCHT) with 3-weekly full dose docetaxel and complete androgen blockade (CAB) in locally advanced and high-risk prostate cancer patients (LAPC) undergoing RP. **METHODS:** Patients (n = 30) were selected by Kattans' preoperative score and received trimestral buserelin 9,45 mg, bicalutamide 50 mg/day and 3 cycles docetaxel (75 mg/m²) followed by RP. Primary endpoints were biochemical (PSA) and local downstaging. Secondary endpoints included toxicity and operability assessments, pathological complete response (pCR), time to PSA progression, 5-year biochemical recurrence free survival (bRFS) and overall survival (OS). **RESULTS:** Median baseline PSA was 25.8 ng/ml (2.1-293), and the predicted probability of 5-year bRFS was 10% (0-55). NCHT induced PSA-reduction was 97.3% (81.3-99.9%; p < 0.001) and post-RP 96.7% of patients were therapy responders, with undetectable PSA-values. Post- vs. pretreatment MRI indicated a median tumor volume reduction of 46.4% (-31.3-82.8; p < 0.001). A pathological downstaging was observed in 48.3%. Severe hematologic toxicities (≥CTC3) were frequent with 53.8% leucopenia, 90% neutropenia and 13.3% febrile neutropenia. RP was performed in all patients. While resectability was hindered in 26.7%, continence was achieved in 96.7%. Pathologic analyses revealed no pCR. Lymph node- and extracapsular involvement was observed in 36.7% and 56.7% with 33.3% positive surgical margins. After a median of 48.6 (19.9-87.8) months, 55.2% of therapy responders experienced PSA-recurrence. The estimated median time to PSA-progression was 38.6 months (95%CI 30.9-46.4) and 85.3 months (95%CI 39.3-131.3) for OS. The 5-year bRFS was improved to 40%, but limiting for interpretation adjuvant treatment was individuali…
relates to:
  type:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/artifact-relationship-type
        l: artifact-relationship-type
      code:
        v: cites
      display:
        v: Cites
  classifier:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/citation-artifact-classifier
        l: citation-artifact-classifier
      code:
        v: D016428
      display:
        v: Journal Article
  citation:
    v: Kattan MW, Eastham JA, Stapleton AMF, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst. 1998;90:766–771. doi: 10.1093/jnci/90.10.766.
  target: Uri
    v: https://pubmed.ncbi.nlm.nih.gov/9605647/
    l: https://pubmed.ncbi.nlm.nih.gov/9605647/
relates to:
  type:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/artifact-relationship-type
        l: artifact-relationship-type
      code:
        v: cites
      display:
        v: Cites
  classifier:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/citation-artifact-classifier
        l: citation-artifact-classifier
      code:
        v: D016428
      display:
        v: Journal Article
  citation:
    v: D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280(11):969–974. doi: 10.1001/jama.280.11.969.
  target: Uri
    v: https://pubmed.ncbi.nlm.nih.gov/9749478/
    l: https://pubmed.ncbi.nlm.nih.gov/9749478/
relates to:
  type:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/artifact-relationship-type
        l: artifact-relationship-type
      code:
        v: cites
      display:
        v: Cites
  classifier:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/citation-artifact-classifier
        l: citation-artifact-classifier
      code:
        v: D016428
      display:
        v: Journal Article
  citation:
    v: Sonpavde G, Sternberg CN. Neoadjuvant systemic therapy for urological malignancies. BJU Int. 2010;106(1):6–22.
  target: Uri
    v: https://pubmed.ncbi.nlm.nih.gov/20553475/
    l: https://pubmed.ncbi.nlm.nih.gov/20553475/
relates to:
  type:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/artifact-relationship-type
        l: artifact-relationship-type
      code:
        v: cites
      display:
        v: Cites
  classifier:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/citation-artifact-classifier
        l: citation-artifact-classifier
      code:
        v: D016428
      display:
        v: Journal Article
  citation:
    v: Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Mattelaer J, Lopez Torecilla J, Pfeffer JR, Lino Cutajar C, Zurlo A, Pierart M. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. 2002;360(9327):103–106. doi: 10.1016/S0140-6736(02)09408-4.
  target: Uri
    v: https://pubmed.ncbi.nlm.nih.gov/12126818/
    l: https://pubmed.ncbi.nlm.nih.gov/12126818/
relates to:
  type:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/artifact-relationship-type
        l: artifact-relationship-type
      code:
        v: cites
      display:
        v: Cites
  classifier:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/citation-artifact-classifier
        l: citation-artifact-classifier
      code:
        v: D016428
      display:
        v: Journal Article
  citation:
    v: Warde P, Mason M, Ding K, Kirkbride P, Brundage M, Cowan R, Gospodarowicz M, Sanders K, Kostashuk E, Swanson G, Barber J, Hiltz A, Parmar MK, Sathya J, Anderson J, Hayter C, Hetherington J, Sydes MR, Parulekar W, NCIC CTG. PR.3/MRC UK PR07 investigators. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet. 2011;378(9809):2104–2111. doi: 10.1016/S0140-6736(11)61095-7.
  target: Uri
    v: https://pubmed.ncbi.nlm.nih.gov/22056152/
    l: https://pubmed.ncbi.nlm.nih.gov/22056152/
relates to:
  type:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/artifact-relationship-type
        l: artifact-relationship-type
      code:
        v: cites
      display:
        v: Cites
  classifier:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/citation-artifact-classifier
        l: citation-artifact-classifier
      code:
        v: D016428
      display:
        v: Journal Article
  citation:
    v: Shelley MD, Kumar S, Wilt T, Staffurth J, Coles B, Mason MD. A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma. Cancer Treat Rev. 2009;35(1):9–17. doi: 10.1016/j.ctrv.2008.08.002.
  target: Uri
    v: https://pubmed.ncbi.nlm.nih.gov/18926640/
    l: https://pubmed.ncbi.nlm.nih.gov/18926640/

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/artifact-relationship-type
      l: artifact-relationship-type
    code:
      v: cites
    display:
      v: Cites
classifier:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Prayer-Galetti T, Sacco E, Pagano F, Gardiman M, Cisternino A, Betto G, Sperandio P. Long-term follow-up of a neoadjuvant chemohormonal taxane-based phase II trial before radical prostatectomy in patients with non-metastatic high-risk prostate cancer. BJU Int. 2007;100(2):274–280. doi: 10.1111/j.1464-410X.2007.06760.x.
target: Uri
  v: https://pubmed.ncbi.nlm.nih.gov/17355369/
  l: https://pubmed.ncbi.nlm.nih.gov/17355369/

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/artifact-relationship-type
      l: artifact-relationship-type
    code:
      v: cites
    display:
      v: Cites
classifier:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513–1520. doi: 10.1056/NEJMoa041318.
target: Uri
  v: https://pubmed.ncbi.nlm.nih.gov/15470214/
  l: https://pubmed.ncbi.nlm.nih.gov/15470214/

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/artifact-relationship-type
      l: artifact-relationship-type
    code:
      v: cites
    display:
      v: Cites
classifier:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008;26(2):242–245. doi: 10.1200/JCO.2007.12.4008.
target: Uri
  v: https://pubmed.ncbi.nlm.nih.gov/18182665/
  l: https://pubmed.ncbi.nlm.nih.gov/18182665/

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/artifact-relationship-type
      l: artifact-relationship-type
    code:
      v: cites
    display:
      v: Cites
classifier:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Sartor AO. Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space. J Hematol Oncol. 2011;4:18. doi: 10.1186/1756-8722-4-18.
target: Uri
  v: https://pubmed.ncbi.nlm.nih.gov/21513551/
  l: https://pubmed.ncbi.nlm.nih.gov/21513551/

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/artifact-relationship-type
      l: artifact-relationship-type
    code:
      v: cites
    display:
      v: Cites
classifier:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Huang X, Chau CH, Figg WD. Challenges to improved therapeutics for metastatic castrate resistant prostate cancer: from recent successes and failures. J Hematol Oncol. 2012;5:35. doi: 10.1186/1756-8722-5-35.
target: Uri
  v: https://pubmed.ncbi.nlm.nih.gov/22747660/
  l: https://pubmed.ncbi.nlm.nih.gov/22747660/

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/artifact-relationship-type
      l: artifact-relationship-type
    code:
      v: cites
    display:
      v: Cites
classifier:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Dreicer R, Magi-Galluzzi C, Zhou M, Rothaermel J, Reuther A, Ulchaker J, Zippe C, Fergany A, Klein EA. Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer. Urology. 2004;63(6):1138–1142. doi: 10.1016/j.urology.2004.01.040.
target: Uri
  v: https://pubmed.ncbi.nlm.nih.gov/15183967/
  l: https://pubmed.ncbi.nlm.nih.gov/15183967/

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/artifact-relationship-type
      l: artifact-relationship-type
    code:
      v: cites
    display:
      v: Cites
classifier:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Febbo PG, Richie JP, George DJ, Loda M, Manola J, Shankar S, Barnes AS, Tempany C, Catalona W, Kantoff PW, Oh WK. Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res. 2005;11(14):5233–5240. doi: 10.1158/1078-0432.CCR-05-0299.
target: Uri
  v: https://pubmed.ncbi.nlm.nih.gov/16033841/
  l: https://pubmed.ncbi.nlm.nih.gov/16033841/

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/artifact-relationship-type
      l: artifact-relationship-type
    code:
      v: cites
    display:
      v: Cites
classifier:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Magi-Galluzzi C, Zhou M, Reuther AM, Dreicer R, Klein EA. Neoadjuvant docetaxel treatment for locally advanced prostate cancer: a clinicopathologic study. Cancer. 2007;110(6):1248–1254. doi: 10.1002/cncr.22897.
target: Uri
  v: https://pubmed.ncbi.nlm.nih.gov/17674353/
  l: https://pubmed.ncbi.nlm.nih.gov/17674353/

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/artifact-relationship-type
      l: artifact-relationship-type
    code:
      v: cites
    display:
      v: Cites
classifier:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Mellado B, Font A, Alcaraz A, Aparicio LA, Veiga FJ, Areal J, Gallardo E, Hannaoui N, Lorenzo JR, Sousa A, Fernandez PL, Gascon P. Phase II trial of short-term neoadjuvant docetaxel and complete androgen blockade in high-risk prostate cancer. Br J Cancer. 2009;101(8):1248–1252. doi: 10.1038/sj.bjc.6605320.
target: Uri
  v: https://pubmed.ncbi.nlm.nih.gov/19755998/
  l: https://pubmed.ncbi.nlm.nih.gov/19755998/

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/artifact-relationship-type
      l: artifact-relationship-type
    code:
      v: cites
    display:
      v: Cites
classifier:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Chi KN, Chin JL, Winquist E, Klotz L, Saad F, Gleave ME. Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer. J Urol. 2008;180(2):565–570. doi: 10.1016/j.juro.2008.04.012.
target: Uri
  v: https://pubmed.ncbi.nlm.nih.gov/18554663/
  l: https://pubmed.ncbi.nlm.nih.gov/18554663/

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/artifact-relationship-type
      l: artifact-relationship-type
    code:
      v: cites
    display:
      v: Cites
classifier:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Sella A, Zisman A, Kovel S, Yarom N, Leibovici D, Lindner A. Neoadjuvant chemohormonal therapy in poor-prognosis localized prostate cancer. Urology. 2008;71(2):323–327. doi: 10.1016/j.urology.2007.08.060.
target: Uri
  v: https://pubmed.ncbi.nlm.nih.gov/18308112/
  l: https://pubmed.ncbi.nlm.nih.gov/18308112/

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/artifact-relationship-type
      l: artifact-relationship-type
    code:
      v: cites
    display:
      v: Cites
classifier:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Narita S, Tsuchiya N, Kumazawa T, Maita S, Numakura K, Obara T, Tsuruta H, Saito M, Inoue T, Horikawa Y, Satoh S, Nanjyo H, Habuchi T. Short-term clinicopathological outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade, followed by treatment with docetaxel and estramustine phosphate before radical prostatectomy in Japanese patients with high-risk localized prostate cancer. World J Surg Oncol. 2012;10:1. doi: 10.1186/1477-7819-10-1.
target: Uri
  v: https://pubmed.ncbi.nlm.nih.gov/22214417/
  l: https://pubmed.ncbi.nlm.nih.gov/22214417/

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/artifact-relationship-type
      l: artifact-relationship-type
    code:
      v: cites
    display:
      v: Cites
classifier:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: van der Kwast TH, Têtu B, Candas B, Gomez JL, Cusan L, Labrie F. Prolonged neoadjuvant combined androgen blockade leads to a further reduction of prostatic tumor volume: three versus six months of endocrine therapy. Urology. 1999;53(3):523–529. doi: 10.1016/S0090-4295(98)00542-1.
target: Uri
  v: https://pubmed.ncbi.nlm.nih.gov/10096378/
  l: https://pubmed.ncbi.nlm.nih.gov/10096378/

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/artifact-relationship-type
      l: artifact-relationship-type
    code:
      v: cites
    display:
      v: Cites
classifier:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Hu JC, Elkin EP, Pasta DJ, Lubeck DP, Kattan MW, Carroll PR, Litwin MS. Predicting quality of life after radical prostatectomy: results from CaPSURE. J Urol. 2004;171(2 Pt 1):703–708.
target: Uri
  v: https://pubmed.ncbi.nlm.nih.gov/14713791/
  l: https://pubmed.ncbi.nlm.nih.gov/14713791/

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/artifact-relationship-type
      l: artifact-relationship-type
    code:
      v: cites
    display:
      v: Cites
classifier:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Kim WY, Whang YE, Pruthi RS, Baggstrom MQ, Rathmell WK, Rosenman JG, Wallen EM, Goyal LK, Grigson G, Watkins C, Godley PA. Neoadjuvant docetaxel/estramustine prior to radical prostatectomy or external beam radiotherapy in high risk localized prostate cancer: a phase II trial. Urol Oncol. 2011;29(6):608–613. doi: 10.1016/j.urolonc.2009.09.012.
target: Uri
  v: https://pubmed.ncbi.nlm.nih.gov/20022268/
  l: https://pubmed.ncbi.nlm.nih.gov/20022268/

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/artifact-relationship-type
      l: artifact-relationship-type
    code:
      v: cites
    display:
      v: Cites
classifier:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Schulman CC, Debruyne FM, Forster G, Selvaggi FP, Zlotta AR, Witjes WP. 4-year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer. Eur Urol. 2000;38(6):706–713. doi: 10.1159/000020366.
target: Uri
  v: https://pubmed.ncbi.nlm.nih.gov/11111188/
  l: https://pubmed.ncbi.nlm.nih.gov/11111188/

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/artifact-relationship-type
      l: artifact-relationship-type
    code:
      v: cites
    display:
      v: Cites
classifier:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Hussain M, Smith DC, El-Rayes BF, Du W, Vaishampayan U, Fontana J, Sakr W, Wood D. Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locallyadvanced prostate cancer. Urology. 2003;61(4):774–780. doi: 10.1016/S0090-4295(02)02519-0.
target: Uri
  v: https://pubmed.ncbi.nlm.nih.gov/12670564/
  l: https://pubmed.ncbi.nlm.nih.gov/12670564/

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/artifact-relationship-type
      l: artifact-relationship-type
    code:
      v: cites
    display:
      v: Cites
classifier:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Eastham JA, Kelly WK, Grossfeld GD, Small EJ. Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease. Urology. 2003;62(Suppl 1):55–62.
target: Uri
  v: https://pubmed.ncbi.nlm.nih.gov/14747042/
  l: https://pubmed.ncbi.nlm.nih.gov/14747042/

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/artifact-relationship-type
      l: artifact-relationship-type
    code:
      v: cites
    display:
      v: Cites
classifier:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: D’Amico AV, Chang E, Garnick M, Kantoff P, Jiroutek M, Tempany CM. Assessment of prostate cancer volume using endorectal coil magnetic resonance imaging: a new predictor of tumor response to neoadjuvant androgen suppression therapy. Urology. 1998;51(2):287–292. doi: 10.1016/S0090-4295(97)00610-9.
target: Uri
  v: https://pubmed.ncbi.nlm.nih.gov/9495713/
  l: https://pubmed.ncbi.nlm.nih.gov/9495713/

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/artifact-relationship-type
      l: artifact-relationship-type
    code:
      v: cites
    display:
      v: Cites
classifier:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: D’Amico AV, Halabi S, Tempany C, Titelbaum D, Philips GK, Loffredo M, McMahon E, Sanford B, Vogelzang NJ, Small EJ. Cancer and Leukemia Group B. Tumor volume changes on 1.5 tesla endorectal MRI during neoadjuvant androgen suppression therapy for higher-risk prostate cancer and recurrence in men treated using radiation therapy results of the phase II CALGB 9682 study. Int J Radiat Oncol Biol Phys. 2008;71(1):9–15. doi: 10.1016/j.ijrobp.2007.09.033.
target: Uri
  v: https://pubmed.ncbi.nlm.nih.gov/18037582/
  l: https://pubmed.ncbi.nlm.nih.gov/18037582/

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/artifact-relationship-type
      l: artifact-relationship-type
    code:
      v: cites
    display:
      v: Cites
classifier:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Vuky J, Porter C, Isacson C, Vaughan M, Kozlowski P, Picozzi V, Corman J. Phase II trial of neoadjuvant docetaxel and gefitinib followed by radical prostatectomy in patients with high-risk, locally advanced prostate cancer. Cancer. 2009;115(4):784–791. doi: 10.1002/cncr.24092.
target: Uri
  v: https://pubmed.ncbi.nlm.nih.gov/19130458/
  l: https://pubmed.ncbi.nlm.nih.gov/19130458/

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/artifact-relationship-type
      l: artifact-relationship-type
    code:
      v: cites
    display:
      v: Cites
classifier:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, Van der Kwast T, Wiegel T, Zattoni F, Heidenreich A. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2011;59(4):572–583. doi: 10.1016/j.eururo.2011.01.025.
target: Uri
  v: https://pubmed.ncbi.nlm.nih.gov/21315502/
  l: https://pubmed.ncbi.nlm.nih.gov/21315502/

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/artifact-relationship-type
      l: artifact-relationship-type
    code:
      v: cites
    display:
      v: Cites
classifier:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Sildenafil Study Group. Oral sildenafil in the treatment of erectile dysfunction. 1998. J Urol. 2002;167(2 Pt 2):1197–1203.
target: Uri
  v: https://pubmed.ncbi.nlm.nih.gov/11905901/
  l: https://pubmed.ncbi.nlm.nih.gov/11905901/

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/artifact-relationship-type
      l: artifact-relationship-type
    code:
      v: cites
    display:
      v: Cites
classifier:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, Figg WD, Freidlin B, Halabi S, Hudes G, Hussain M, Kaplan R, Myers C, Oh W, Petrylak DP, Reed E, Roth B, Sartor O, Scher H, Simons J, Sinibaldi V, Small EJ, Smith MR, Trump DL, Robin V, Wilding G. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 1999;17(11):3461–3467.
target: Uri
  v: https://pubmed.ncbi.nlm.nih.gov/10550143/
  l: https://pubmed.ncbi.nlm.nih.gov/10550143/

published in:
  type:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/published-in-type
        l: published-in-type
      code:
        v: D020492
      display:
        v: Periodical
  identifier:
    type:
      text:
        v: Electronic ISSN Type
    system:
      v: https://portal.issn.org
      l: portal.issn.org
    value:
      v: 1756-8722
  identifier:
    type:
      text:
        v: ISOAbbreviation
    system:
      v: https://www.issn.org/services/online-services/access-to-the-ltwa/
      l: access-to-the-ltwa
    value:
      v: J Hematol Oncol
  identifier:
    type:
      text:
        v: ISSN Linking
    system:
      v: https://www.issn.org/understanding-the-issn/assignment-rules/the-issn-l-for-publications-on-multiple-media/
      l: the-issn-l-for-publications-on-multiple-media
    value:
      v: 1756-8722
  identifier:
    type:
      text:
        v: Medline Title Abbreviation
    system:
      v: https://www.nlm.nih.gov/tsd/cataloging/contructitleabbre.html
      l: contructitleabbre.html
    value:
      v: J Hematol Oncol
  identifier:
    type:
      text:
        v: NLM Unique ID
    system:
      v: https://locatorplus.gov/cgi-bin/Pwebrecon.cgi
      l: https://locatorplus.gov/cgi-bin/Pwebrecon.cgi
    value:
      v: 101468937
  title:
    v: Journal of hematology & oncology
  publisher location:
    v: England
cited medium:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-medium
      l: cited-medium
    code:
      v: internet
    display:
      v: Internet
volume:
  v: 7
article date:
  v: 2014-03-05
page string:
  v: 20

v: Electronic

v: Electronic

v: XX

v: Organization identifier

v: XX

v: Organization identifier

v: XX

v: Organization identifier

v: XX

v: Organization identifier

cited medium:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-medium
      l: cited-medium
    code:
      v: internet-without-issue
    display:
      v: Internet without issue
article date:
  v: 2014-03-05

classifier:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/artifact-url-classifier
      l: artifact-url-classifier
    code:
      v: abstract
    display:
      v: Abstract
url:
  v: https://pubmed.ncbi.nlm.nih.gov/24598155/
  l: https://pubmed.ncbi.nlm.nih.gov/24598155/

classifier:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/artifact-url-classifier
      l: artifact-url-classifier
    code:
      v: doi-based
    display:
      v: DOI Based
url:
  v: https://doi.org/10.1186/1756-8722-7-20
  l: https://doi.org/10.1186/1756-8722-7-20

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: publishing-model
    display:
      v: Publishing Model
    user selected:
      v: false
classifier:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: Electronic
    display:
      v: Electronic
    user selected:
      v: false

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: chemical
    display:
      v: Chemical
    user selected:
      v: false
classifier: D000726
  coding:
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D000726
    display:
      v: Androgen Antagonists
    user selected:
      v: false
classifier: D043823
  coding:
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D043823
    display:
      v: Taxoids
    user selected:
      v: false
classifier: http://id.nlm.nih.gov/mesh/D000077143
  coding:
    system:
      v: https://www.cas.org/support/documentation/chemical-substances
      l: chemical-substances
    code:
      v: 15H5577CQD
    user selected:
      v: false
  coding:
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D000077143
    display:
      v: Docetaxel
    user selected:
      v: false

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: mesh-heading
    display:
      v: MeSH heading
artifact assessment:
  l: meshHeading0
  reference:
    v: #meshHeading0
  type:
    v: ArtifactAssessment
    l: ArtifactAssessment

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: publication-type
    display:
      v: Publication type
classifier: D017427
  coding:
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D017427
    display:
      v: Clinical Trial, Phase II
    user selected:
      v: false
classifier: D016428
  coding:
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D016428
    display:
      v: Journal Article
    user selected:
      v: false

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: knowledge-artifact-type
    display:
      v: Knowledge Artifact Type
    user selected:
      v: false
classifier:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
    user selected:
      v: false
artifact assessment:
  display:
    v: Classifier added by Computable Publishing LLC

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: citation-subset
    display:
      v: Citation subset
    user selected:
      v: false
classifier:
  coding:
    system:
      v: https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#citationsubset
      l: citationsubset
    code:
      v: IM
    display:
      v: IM
    user selected:
      v: false

complete:
  v: true
entry:
  contributor:
    l: contributor0
    reference:
      v: #contributor0
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Thalgott M
  forename initials:
    v: M
  affiliation:
    display:
      v: Department of Urology, Klinikum rechts der Isar, Technische Universität München, Ismaninger Str, 22, Munich 81675, Germany. mark.thalgott@lrz.tum.de.
entry:
  contributor:
    l: contributor1
    reference:
      v: #contributor1
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Horn T
  forename initials:
    v: T
entry:
  contributor:
    l: contributor2
    reference:
      v: #contributor2
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Heck MM
  forename initials:
    v: MM
entry:
  contributor:
    l: contributor3
    reference:
      v: #contributor3
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Maurer T
  forename initials:
    v: T
entry:
  contributor:
    l: contributor4
    reference:
      v: #contributor4
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Eiber M
  forename initials:
    v: M
entry:
  contributor:
    l: contributor5
    reference:
      v: #contributor5
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Retz M
  forename initials:
    v: M
entry:
  contributor:
    l: contributor6
    reference:
      v: #contributor6
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Autenrieth M
  forename initials:
    v: M
entry:
  contributor:
    l: contributor7
    reference:
      v: #contributor7
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Herkommer K
  forename initials:
    v: K
entry:
  contributor:
    l: contributor8
    reference:
      v: #contributor8
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Krause BJ
  forename initials:
    v: BJ
entry:
  contributor:
    l: contributor9
    reference:
      v: #contributor9
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Gschwend JE
  forename initials:
    v: JE
entry:
  contributor:
    l: contributor10
    reference:
      v: #contributor10
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Treiber U
  forename initials:
    v: U
entry:
  contributor:
    l: contributor11
    reference:
      v: #contributor11
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Kübler HR
  forename initials:
    v: HR